Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026

EHTH vs EBS: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

EBS Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 5–5 Matrix Metrics)

EBS Overall Winner 6-Pillar Tally: EHTH 2 – 4 EBS Matrix Metrics: EHTH 5 – 5 EBS

As of Nov 17, 2026, Emergent Biosolutions, Inc. (EBS) is the stronger overall head-to-head candidate over eHealth, Inc. (EHTH) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Balance Sheet & Cash Flow, Options & Positioning). EHTH carries a Unified Composite Score of 40.8/100 (SELL) at $0.35 (0.2x Forward P/E, 11.9% operating margin), whereas EBS carries 54.3/100 (HOLD) at $5.63 (20.0x Forward P/E, 5.8% operating margin).

  • Technical & Structure Timing Caution: EHTH is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 24.9); meanwhile EBS trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 37.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About EHTH vs EBS
EHTH NASDAQ
eHealth, Inc.
Insurance Agents, Brokers & Service
$0.35
-9.36% 1D
Market Cap $13.4M
TTM Revenue $469M
Forward P/E 0.2x
Beta / 30D Vol 1.61β · 117% Vol
Unified Composite Score
40.8 / 100 SELL
Tech 25.0 Fund 44.0 Flow 50.0 Mom 63.9
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -28.4%), weak momentum, RSI 25
RSI-14: 24.9 · SMA20: $0.50 · SMA50: $0.65
EBS NYSE Head-to-Head Winner
Emergent Biosolutions, Inc.
Pharmaceutical Preparations
$5.63
-3.1% 1D
Market Cap $297.7M
TTM Revenue $649M
Forward P/E 20.0x
Beta / 30D Vol 0.81β · 49% Vol
Unified Composite Score
54.3 / 100 HOLD
Tech 58.0 Fund 55.0 Flow 68.0 Mom 64.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 38
RSI-14: 37.8 · SMA20: $6.24 · SMA50: $6.49

6-Pillar Scorecard Institutional Category Breakdown (EHTH 2 – 4 EBS)

Columns: Metric · EHTH · EBS
1. Valuation Multiples EHTH
Forward P/E 0.2x 20.0x
Trailing P/E 0.2x 20.0x
PEG Ratio 0.72x 0.38x
EV / Revenue N/M 1.0x
2. Growth & Scale EBS
Revenue Growth (YoY) -60.5% -52.4%
Earnings Growth (YoY) -17.6% -93.8%
TTM Revenue (USD) $469M $649M
Market Cap $13.4M $297.7M
3. Profitability & Quality EHTH
Gross Margin 100.0% 43.4%
Operating Margin 11.9% 5.8%
Net Profit Margin 4.9% -40.2%
Return on Equity (ROE) 2.6% -58.2%
4. Balance Sheet & Cash Flow EBS
Cash Generation (TTM) $58M EBITDA $188M
Cash Flow Margin 12.4% EBITDA Mgn 29.0%
Net Cash / Leverage $15.36 Book/Sh · 2.6% ROE $332M Net Debt (1.62x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning EBS
Options Structure Phase UNCLASSIFIED CONSOLIDATION
Current IV / %ile 128.7% (56th %ile) 73.2% (4th %ile)
Put/Call OI Skew N/A 0.07x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markdown DISTRIBUTION · Neutral
6. R&D & Supply-Chain Moat EBS
OpEx & R&D Intensity N/A 37.6% of Rev ($244M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Insurance Brokers Operator Drug Manufacturers - Specialty & Generic Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: EHTH (5) vs EBS (5)
Institutional Metric EHTH EBS Criterion Row Edge
Market Capitalization
Scale
$13.4M $297.7M Larger Scale EBS
Trailing P/E Ratio
Valuation
0.2x 20.0x Lower Multiple EHTH
Forward P/E Ratio
Valuation
0.2x 20.0x Lower Multiple EHTH
Revenue Growth (YoY)
Growth
-60.5% -52.4% Higher Growth EBS
Operating Margin (TTM)
Profitability
11.9% 5.8% Higher Margin EHTH
Net Profit Margin
Profitability
4.9% -40.2% Higher Margin EHTH
Return on Equity (ROE)
Capital Efficiency
2.6% -58.2% Higher ROE EHTH
52-Week Range Position
Momentum
0% ($0–$5) 13% ($4–$14) Stronger Trend EBS
Beta / 30D Volatility
Risk Regime
1.61β · 117% Vol 0.81β · 49% Vol Lower Realized Risk EBS
Unified Institutional Score
Composite Signal
40.8 / 100 (SELL) 54.3 / 100 (HOLD) Higher Composite EBS
Trailing 12M Revenue (USD)
Operating Scale
$469M $649M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
100.0% 43.4% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
0.72x PEG · N/M EV/Rev 0.38x PEG · 1.0x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$58M EBITDA ($15.36 Book/Sh · 2.6% ROE) $188M ($332M Net Debt (1.62x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon EBS +27.15 pp
EHTH: -38.63% · EBS: -11.48%
3M Horizon EBS +87.16 pp
EHTH: -72.03% · EBS: +15.13%
6M Horizon EBS +50.15 pp
EHTH: -80.3% · EBS: -30.15%
1Y Horizon EBS +46.61 pp
EHTH: -90.92% · EBS: -44.31%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on EHTH vs EBS. Trailing 12-month operating profitability (EHTH 11.9% vs EBS 5.8%) and valuation multiples (EHTH 0.2x vs EBS 20.0x Forward P/E) are benchmarked directly in Pillar 4 below.

EHTH ADR TTM Benchmark FX-Normalized USD
TTM Revenue$469M
Gross Margin100.0%
Op. Margin11.9%
ROE / Fwd P/E2.6% · 0.2x
EBS ADR TTM Benchmark FX-Normalized USD
TTM Revenue$649M
Gross Margin43.4%
Op. Margin5.8%
ROE / Fwd P/E-58.2% · 20.0x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
EHTH UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 128.7%
IV Percentile 56th %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact EHTH Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
EBS CONSOLIDATION
31d in phase · OBV DISTRIBUTION
Current IV 73.2%
IV Percentile 4th %ile
Put/Call OI Skew 0.07x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact EBS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LIVE OPTIONS CHAIN · T+5 TRADING DAY HORIZON Spot $5.81 · IV 78.8%

EBS Simulated 5-Day Option Payoffs vs. Owning 100 Shares ($581)

Compare $581 in 100-share capital outlay against risk-defined 5-day vertical spreads, put-wall income, and 3-leg structures at 78.8% ATM IV.

5-DAY BULLISH SWING Liq C

Dec 18 $6 / $7 Bull Call Spread

Buy 4x $6C · Sell 4x $7C · 32d

Net Entry $180 Debit
T+5d @ +5% Move +$21 (+12%)
Max Risk / Buffer $180 Capped
5d Edge & Liquidity 0.4x R:R · Liq C
Simulate 5-Day Payoff →
ASYMMETRIC 3-LEG STRUCTURE Liq C

Dec 18 $5P / $6-$7C Seagull

Sell 2x $5P · Buy 2x $6/$7C · 32d

Net Entry $60 Debit
T+5d @ +5% Move +$27 (+14.0% RoM)
Max Risk / Buffer -13.9% Put Cushion ($190 Mgn)
5d Edge & Liquidity 0.7x R:R · Liq C
Simulate 5-Day Payoff →

Simulated T+5 trading day payoffs use live option midpoints, bid-ask spread adjustments, and implied volatility skew for educational scenario modeling only — not personalized investment advice. Options involve substantial risk.

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
EHTH Moat Profile Cyclical / Execution-Driven Positioning
Insurance Brokers Operator
Competes within the Insurance Brokers value chain with $13.4M market capitalization and 11.9% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
EBS Moat Profile Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $297.7M market capitalization and 5.8% operating margin.
OpEx & R&D Reinvestment 37.6% of Rev ($244M)
90D Engineering Disclosures 0 Published

Investor FAQ EHTH vs EBS Key Questions & Quantitative Answers

As of Nov 17, 2026, Emergent Biosolutions, Inc. (EBS) is the stronger overall head-to-head candidate over eHealth, Inc. (EHTH) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Balance Sheet & Cash Flow, Options & Positioning). EHTH carries a Unified Composite Score of 40.8/100 (SELL) at $0.35 (0.2x Forward P/E, 11.9% operating margin), whereas EBS carries 54.3/100 (HOLD) at $5.63 (20.0x Forward P/E, 5.8% operating margin). Technical & Structure Timing Caution: EHTH is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 24.9); meanwhile EBS trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 37.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

EBS leads the Growth & Scale pillar: EHTH posts -60.5% YoY revenue growth and -17.6% YoY earnings growth on $469M TTM revenue (100.0% gross margin, 11.9% operating margin), compared with EBS at -52.4% YoY revenue growth and -93.8% YoY earnings growth on $649M TTM revenue (43.4% gross margin, 5.8% operating margin). On trailing 12-month operating scale, EHTH generates $469M in USD-normalized revenue versus $649M for EBS. In operating R&D and SG&A reinvestment, EHTH deploys N/A (0 90-day corporate R&D disclosures) versus 37.6% of Rev ($244M) (0 disclosures) for EBS.

EHTH screens cheaper on headline valuation multiples. EHTH trades at 0.2x Forward P/E, 0.2x Trailing P/E, 0.72x PEG, and N/M EV/Revenue (12.4% EBITDA margin), whereas EBS trades at 20.0x Forward P/E, 20.0x Trailing P/E, 0.38x PEG, and 1.0x EV/Revenue (29.0% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against EHTH (2.6% ROE) versus EBS (-58.2% ROE) capital efficiency.

In options market volatility and institutional positioning, EHTH carries 128.7% implied volatility (56th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.61β · 117% Vol realized risk). By comparison, EBS carries 73.2% implied volatility (4th %ile, Compressed (<25th %ile)), a 0.07x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.81β · 49% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.